Winton Group’s Emergent Biosolutions EBS Stock Holding History

Winton Group’s Portfolio EBS Stock Details EBS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$111K	Sell	13,329 -15,768	-54%	-$163K	﹤0.01%	1034
2025 Q4	$360K	Buy	29,097 +8,681	+43%	+$93K	0.01%	705
2025 Q3	$180K	Buy	+20,416	New	+$159K	0.01%	679
2022 Q1	–	Sell	-39,524	Closed	-$1.72M	–	1012
2021 Q4	$1.72M	Buy	+39,524	New	+$1.79M	0.1%	273
2018 Q3	–	Sell	-5,557	Closed	-$281K	–	1040
2018 Q2	$281K	Sell	5,557 -204	-4%	-$10.6K	0.01%	856
2018 Q1	$303K	Buy	+5,761	New	+$287K	0.01%	975

Other funds holding EBS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PCM

Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Winton Group's EBS Position: Q1 2026 in Review

Winton Group reduced its Emergent Biosolutions (EBS) stake by 54% in Q1 2026, selling an estimated $163K and leaving 13,329 shares worth $111K. The position accounts for ﹤0.01% of the portfolio, ranked #1034.

Winton Group first reported a position in EBS in Q1 2018 and has held it in 6 quarters since. The position peaked at $1.72M in Q4 2021. 190 funds tracked by Wall St. Rank hold EBS as of Q1 2026.

Winton Group held 13,329 shares of Emergent Biosolutions worth $111K as of Q1 2026.
Winton Group sold 15,768 Emergent Biosolutions shares in Q1 2026, an estimated $163K.
Emergent Biosolutions made up ﹤0.01% of Winton Group's portfolio in Q1 2026, its #1034 holding.
Winton Group first reported a position in Emergent Biosolutions in Q1 2018 and has held it in 6 quarters since.
Winton Group's Emergent Biosolutions position peaked at $1.72M in Q4 2021.
190 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.